Atlas Trials

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Clinical trial NCT04900623 · RECRUITING

Trial details

NCT number
NCT04900623
Sponsor
Jonathan Schoenfeld, MD, MPH
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HPV-Associated Oropharyngeal Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 StageHPV-Related Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical StageHPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Start date
2021-07-02
Primary completion
2030-06-01
Enrollment
145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.